Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings
Launched by EYSZ, INC. · Oct 19, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a smartphone app designed to help identify absence seizures in children, which are brief episodes where a child may seem to "zone out" or stare blankly. The study involves children who have experienced these types of seizures as well as those who have not. Participants will go through a safe breathing exercise called hyperventilation, where they take quick, deep breaths. During this exercise, the app will record video of the child's face and any sounds they make, which will help researchers see if the app can accurately detect these seizures.
To be eligible for this study, children must have a history of typical absence seizures, while those with other types of seizures or certain medical conditions may not be able to participate. The trial is open to all children aged between 4 to 12 years. Participants can expect to use the app during a regular EEG test, which is a procedure that monitors brain activity. This study could help improve how absence seizures are detected, making it easier for doctors to diagnose and treat children with epilepsy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • typical absence seizure during use of the Eysz Hyperventilation Recorder or Control
- Exclusion Criteria:
- • Other seizure type besides typical absence seizure during use of the Eysz Hyperventilation Recorder
- • subclinical seizure activity
- • inability to participate with study procedures
- • contraindications to hyperventilation including history of subarachnoid hemorrhage, sickle cell anemia, recent cerebrovascular accident or myocardial infarction, significant cardiopulmonary disease, active asthma, known aneurysm, known moyamoya disease, or pregnancy.
- • People who have a history of generalized tonic clonic convulsions (GTCs) provoked by hyperventilation
About Eysz, Inc.
eysz, inc. is an innovative biopharmaceutical company dedicated to advancing healthcare through the development of novel therapeutic solutions. With a focus on unmet medical needs, eysz, inc. leverages cutting-edge research and technology to drive clinical trials that aim to improve patient outcomes. The company is committed to adhering to the highest standards of clinical practice and regulatory compliance, fostering collaboration with healthcare professionals and regulatory bodies to ensure the successful translation of scientific discoveries into effective treatments. Through its robust pipeline of clinical trials, eysz, inc. strives to make a meaningful impact on the lives of patients and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported